DC 欄位 | 值 | 語言 |
dc.contributor | 臺大醫院;臺大醫院-內科部;臺大醫院-腫瘤醫學部; | en |
dc.contributor.author | Ueno H. | en_US |
dc.contributor.author | Ioka T. | en_US |
dc.contributor.author | Ikeda M. | en_US |
dc.contributor.author | Ohkawa S. | en_US |
dc.contributor.author | Yanagimoto H. | en_US |
dc.contributor.author | Boku N. | en_US |
dc.contributor.author | Fukutomi A. | en_US |
dc.contributor.author | Sugimori K. | en_US |
dc.contributor.author | Baba H. | en_US |
dc.contributor.author | Yamao K. | en_US |
dc.contributor.author | Shimamura T. | en_US |
dc.contributor.author | Sho M. | en_US |
dc.contributor.author | Kitano M. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Mizumoto K. | en_US |
dc.contributor.author | Chen J.-S. | en_US |
dc.contributor.author | Furuse J. | en_US |
dc.contributor.author | Funakoshi A. | en_US |
dc.contributor.author | Hatori T. | en_US |
dc.contributor.author | Yamaguchi T. | en_US |
dc.contributor.author | Egawa S. | en_US |
dc.contributor.author | Sato A. | en_US |
dc.contributor.author | Ohashi Y. | en_US |
dc.contributor.author | Okusaka T. | en_US |
dc.contributor.author | Tanaka M. | en_US |
dc.contributor.author | 鄭安理 | zh-tw |
dc.creator | Ueno, Hideki;Ioka, Tatsuya;Ikeda, Masafumi;Ohkawa, Shinichi;Yanagimoto, Hiroaki;Boku, Narikazu;Fukutomi, Akira;Sugimori, Kazuya;Baba, Hideo;Yamao, Kenji;Shimamura, Tomotaka;Sho, Masayuki;Kitano, Masayuki;Cheng, Ann-Lii;Mizumoto, Kazuhiro;Chen, Jen-Shi;Furuse, Junji;Funakoshi, Akihiro;Hatori, Takashi;Yamaguchi, Taketo;Egawa, Shinichi;Sato, Atsushi;Ohashi, Yasuo;Okusaka, Takuji;Tanaka, Masao | en |
dc.creator | 鄭安理 | zh-tw |
dc.date | 2013 | en |
dc.date.accessioned | 2014-02-14T06:32:40Z | - |
dc.date.accessioned | 2018-07-11T06:59:39Z | - |
dc.date.available | 2014-02-14T06:32:40Z | - |
dc.date.available | 2018-07-11T06:59:39Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/259260 | - |
dc.description.abstract | Purpose
The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival.
Patients and Methods
The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle), or gemcitabine plus S-1 (gemcitabine 1,000 mg/m2 on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle).
Results
In the total of 834 enrolled patients, median overall survival was 8.8 months in the gemcitabine group, 9.7 months in the S-1 group, and 10.1 months in the gemcitabine plus S-1 group. The noninferiority of S-1 to gemcitabine was demonstrated (hazard ratio, 0.96; 97.5% CI, 0.78 to 1.18; P < .001 for noninferiority), whereas the superiority of gemcitabine plus S-1 was not (hazard ratio, 0.88; 97.5% CI, 0.71 to 1.08; P = .15). All treatments were generally well tolerated, although hematologic and GI toxicities were more severe in the gemcitabine plus S-1 group than in the gemcitabine group.
Conclusion
Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer. J Clin Oncol 31: 1640-1648. (C) 2013 by American Society of Clinical Oncology | en |
dc.format.extent | 106 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | en-us | en |
dc.relation | J. Clin. Oncol., 31(13), 1640-+ | en |
dc.relation.ispartof | Journal of Clinical Oncology | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | gemcitabine; gimeracil plus oteracil potassium plus tegafur; antineoplastic agent; antineoplastic antimetabolite; deoxycytidine; drug derivative; gemcitabine; oteracil; S 1 (combination); tegafur; acute hepatitis; adult; advanced cancer; aged; anorexia; cancer chemotherapy; cancer combination chemotherapy; cancer survival; Conference Paper; controlled study; diarrhea; drug efficacy; drug safety; drug tolerability; fatigue; febrile neutropenia; female; human; infection; Japan; leukopenia; lung disease; major clinical study; male; metastatic pancreatic cancer; metastatic pancreatic cancer; monotherapy; mucosa inflammation; multiple cycle treatment; nausea; neutropenia; overall survival; pancreas cancer; phase 3 clinical trial; pneumonia; priority journal; quality adjusted life year; randomized controlled trial; rash; second line chemotherapy; sepsis; Taiwan; thrombocytopenia; treatment response; vomiting; article; controlled clinical trial; drug combination; metastasis; middle aged; multicenter study; pancreas tumor; pathology; quality of life; survival; treatment outcome; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Taiwan; Tegafur; Treatment Outcome | - |
dc.title | Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study | en |
dc.identifier.doi | 10.1200/JCO.2012.43.3680 | - |
dc.relation.pages | 1640-1648 | - |
dc.identifier.uri.fulltext | http://ntur.lib.ntu.edu.tw/bitstream/246246/259260/1/index.html | - |
item.fulltext | with fulltext | - |
item.grantfulltext | open | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系
|